Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
The generation of this novel in vitro model of human left ventricular–specific cardiomyocytes harboring GLA mutations provides a rapid disease-relevant platform for studying Fabry cardiomyopathy and broadens opportunities for drug screening and investigation of disease-related molecular mechanisms.
Abstract
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene encoding the enzyme α-galactosidase A (α-Gal A). Enzyme deficiency results in multisystemic pathogenic alterations, including Fabry cardiomyopathy, the leading cause of death in affected patients, whose underlying mechanisms remain incompletely understood.
To develop and characterize a genetically modified human left ventricular cardiomyocyte model derived from induced pluripotent stem cells (LV-iPSCs) in order to investigate the mechanisms underlying Fabry cardiomyopathy.
The CRISPR/Cas9 system was used to generate GLA variants via homology-directed repair with the GLA-N34D guide targeting exon 1. Edited and control cells were subjected to α-Gal A enzymatic activity assays, left ventricular-directed cardiomyocyte differentiation, and electrophysiological analyses.
Gene editing generated two homozygous exon 1 variants: a missense mutation (p.N34D; p.Asn34Asp) and a 25-bp deletion (p.Leu32fs*). Both variants led to frameshift mutations with premature stop codons and nonfunctional proteins, while morphology, pluripotency, and cellular integrity were preserved, as confirmed by immunocytochemistry. Consistent with the FD phenotype, edited cells exhibited no detectable α-Gal A activity compared with controls (80.411 μmol/L/h; p < 0.0001). The left ventricular–directed differentiation protocol significantly shortened the time required to obtain more mature action potentials (APs) compared with the standard cardiomyocyte differentiation protocol (60-day reduction). LV-iPSC–derived cardiomyocytes exhibited increased capacitance, particularly in the presence of 5 µg/mL BMP4, indicating an expanded membrane area and enhanced structural maturation. Despite this, electrophysiological heterogeneity persisted, with predominantly sodium-driven APs and a subset of cells exhibiting calcium-mediated depolarization. These findings indicate that the left ventricular–specific differentiation protocol accelerates acquisition of a more mature ventricular phenotype while preserving subpopulations with electrophysiological features typical of earlier stages of cardiac development.
The generation of this novel in vitro model of human left ventricular–specific cardiomyocytes harboring GLA mutations provides a rapid disease-relevant platform for studying Fabry cardiomyopathy and broadens opportunities for drug screening and investigation of disease-related molecular mechanisms.
Missense variants in PRKAG2, the gene encoding for the γ2-subunit of adenosine monophosphate-activated protein kinase (AMPK), can cause hypertrophic cardiomyopathy, cardiac conduction defects and glycogen storage disorders. Clinical consequences evoked by truncating PRKAG2 variants are poorly understood. Dermal fibrobl...
Benedict Hoffmann, Tim Knochenhauer, J. Schlobohm et al.· Stem Cell Research· 0 citations
Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by enzyme deficiencies that impair glycosaminoglycan degradation and cause multisystem disease. We generated two human induced pluripotent stem cell (iPSC) lines from the KOLF2.1J background using CRISPR/Cas9-mediated knock-in of pathogenic variants: TR...
Chris H. Ma, M. Xu, Yong-Shun Lin et al.· Stem Cell Research· 0 citations
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration and respiratory failure. Approximately 10% of ALS cases are familial, with mutations in
SOD1
representing a major genetic cause. Preservation of physiological SOD1 function may be i...
K. Imamura, Kayoko Tsukita, Shin Yoshioka et al.· BMC Medical Genomics· 0 citations
Friedreich’s ataxia (FRDA) is a multisystemic neurodegenerative disorder caused by GAA repeat expansion in intron 1 of frataxin (FXN), resulting in FXN deficiency and mitochondrial dysfunction. Current therapies do not correct the underlying genetic defect. Here, we demonstrate that ex vivo CRISPR/Cas9 excision of the...
Anusha Sivakumar, Alexis N. Corl, Keneth Jordan Muñoz et al.· Journal of Clinical Investig...· 1 citation· ⚡1
A plasmid-free CRISPR/Cas9 RNP-based approach for targeted Park7 gene editing in primary MEFs is demonstrated and underline the importance of considering both the outcomes of genomic editing and the expression of functional protein when evaluating CRISPR/Cas9 approaches.
BACKGROUND
Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disease caused by mutations in the DMD gene, leading to the absence or dysfunction of dystrophin. Although cardiac and skeletal muscles are both affected, tissue-specific differences in disease manifestation and dystrophin regulation remain...
M. Białobrzeska, M. Przymuszała, Paweł E. Ferdek et al.· Circulation Genomic and Prec...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.